Physician profile
David Knight
NPI 1598969644
$806.21
in general payments reported to CMS, 2019-2025
13 companies · $224 in 2025
The $224 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $59.06 · 2020: $16.57 · 2021: $137 · 2022: $125 · 2023: $128 · 2024: $116 · 2025: $224.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $368 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $368.36 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $163.46 | 2019-2025 | Keytruda, Lynparza |
| Janssen Pharmaceuticals, INC | $124.93 | 2021 | |
| Seagen INC. | $114.22 | 2019-2025 | |
| Taiho Oncology, INC. | $89.59 | 2024-2025 | |
| Bio Products Laboratory USA, INC. | $66.37 | 2022-2023 | Gammaplex, Coagadex |
| Beigene USA, INC. | $55.61 | 2022-2023 | Brukinsa |
| Adc Therapeutics America, INC. | $43.79 | 2022-2023 | |
| E.R. Squibb & Sons, L.L.C. | $38.15 | 2020-2022 | |
| Beone Medicines USA, INC. | $34.16 | 2025 | Brukinsa |
| Tesaro, INC. | $27.29 | 2019 | |
| Celgene Corporation | $23.71 | 2023 | Reblozyl |
| Novartis Pharmaceuticals Corporation | $13.01 | 2023 | |
| Gilead Sciences, INC. | $11.92 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Knight listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.